[{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline","moa":"MMP-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"}]

Find Dermatology Clinical Drug Pipeline Developments & Deals by Endo International

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Details : Doxy 100-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.

                          Product Name : Doxy 100-Generic

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          December 10, 2024

                          Lead Product(s) : Doxycycline

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Details : Qwo® (collagenase clostridium histolyticum-aaes), an FDA-approved injectable is used for the treatment of moderate to severe cellulite in the buttocks of adult women. QWO is contraindicated in patients with a history of hypersensitivity to collagenase.

                          Product Name : Qwo

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          July 10, 2022

                          Lead Product(s) : Collagenase Clostridium Histolyticum

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Details : Qwo (collagenase clostridium histolyticum-aaes), is a prescription medicine used to treat moderate to severe cellulite in the buttocks of adult women, may cause serious side effects including allergic.

                          Product Name : Qwo

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          May 05, 2022

                          Lead Product(s) : Collagenase Clostridium Histolyticum

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AGGSpend
                          Not Confirmed
                          AGGSpend
                          Not Confirmed

                          Details : Endo International will present data relevant to the use of Endo Aesthetics' Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women during the American Society for Dermatologic ...

                          Product Name : Qwo

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          September 10, 2020

                          Lead Product(s) : Collagenase Clostridium Histolyticum

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank